Рыночные новости
Заголовки по акциям и крипте из Alpaca. Храним 7 дней. Всего: 9760.
-
Alamar Biosciences Updates 2026 Revenue GuidanceAlamar Biosciences expects full-year 2026 revenue to be in the range of $121 million to $123 million, surpassing the FactSet estimate of $118.6 million.
-
Alamar Biosciences Reports Q3 2026 RevenueAlamar Biosciences reported Q3 2026 revenue of $33.5 million, exceeding the FactSet consensus estimate of $30.2 million.
-
Alamar Biosciences Announces Strategic Scientific Collaboration with GSKAlamar Biosciences and GSK have entered a strategic scientific collaboration to utilize Alamar's NULISA platform for a large-scale study on protein biomarkers.
-
Jackson Financial Inc. Reports Q3 2026 Financial ResultsJackson Financial Inc. reported third-quarter 2026 financial results, exceeding analyst expectations for adjusted earnings per share.
-
Fairfax India Holdings Corporation Reports Third Quarter 2026 Financial ResultsFairfax India announced net earnings of $37.6 million for the third quarter of 2026, compared to $3.2 million in the same period of 2025.
-
Flywire Corporation Reports Third Quarter 2026 Financial ResultsFlywire Corporation announced its financial results for the third quarter ended September 30, 2026, reporting strong top-line growth and expanded adjusted EBITDA margins.
-
Procore Technologies Reports Q3 2026 Financial Results and Sets Q4 GuidanceProcore Technologies, Inc. reported third-quarter 2026 financial results, exceeding analyst estimates for both revenue and adjusted earnings per share, while providing guidance for the fourth quarter.
-
Curaleaf Evaluates Aurora Cannabis's Alternative Transaction with OrganigramCuraleaf Holdings, Inc. is reviewing the proposed merger between Aurora Cannabis and Organigram while maintaining its own outstanding offer for Aurora.
-
National Energy Services Reunited Corp. Schedules Q3 2026 Earnings AnnouncementNational Energy Services Reunited Corp. (NESR) has scheduled the release of its financial results for the third quarter of 2026 for November 4, 2026.
-
Curaleaf Reports Third Quarter 2026 Financial ResultsCuraleaf Holdings, Inc. announced its financial and operating results for the third quarter ended September 30, 2026, highlighting record revenue and robust profitability.
-
Toast, Inc. Reports Q3 2026 Financial ResultsToast, Inc. reported third-quarter 2026 financial results, exceeding analyst expectations for both revenue and earnings per share.
-
American International Group, Inc. Reports Q3 2026 Financial ResultsAIG reported third-quarter 2026 adjusted earnings per share of $2.06, exceeding analyst expectations of $1.88.
-
Boardwalk REIT Reports Third Quarter 2026 Financial ResultsBoardwalk Real Estate Investment Trust announced its financial results for the third quarter of 2026, reporting Funds From Operations of $1.21 per unit and Same Property Net Operating Income of $98.2 million.
-
Ouster, Inc. Reports Third Quarter 2026 Financial ResultsOuster, Inc. announced its financial results for the third quarter ended September 30, 2026, reporting $59 million in revenue and over 27,000 sensor shipments.
-
Innospec Reports Third Quarter 2026 Financial Results and Dividend DeclarationInnospec Inc. announced its financial results for the third quarter of 2026 and declared a semi-annual dividend of 94 cents per share.
-
Valmont Industries to Participate in Baird's 2026 Global Industrial ConferenceValmont Industries, Inc. announced its scheduled participation in the upcoming Baird 2026 Global Industrial Conference.
-
Navitas Semiconductor Announces Third Quarter 2026 Financial ResultsNavitas Semiconductor reported its third quarter 2026 financial results, highlighting 33% sequential revenue growth and providing guidance for the fourth quarter.
-
Perrigo Company plc Named to Dividend Channel's S.A.F.E. 25 ListPerrigo Company plc has been included in the Dividend Channel S.A.F.E. 25 list, which highlights companies based on specific dividend metrics.
-
Nurix Therapeutics Announces Sanofi's Decision to Discontinue SAR448272 ProgramSanofi has notified Nurix Therapeutics of its decision to terminate the Phase 1 clinical trial and development program for the oral STAT6 degrader SAR448272.
-
Arcus Biosciences Scheduled to Report Third Quarter 2026 Financial ResultsArcus Biosciences, Inc. is scheduled to release its financial results for the third quarter of 2026 on November 4, 2026, after the market closes.